Evidence map›Paper›PMID 23786357›Full record

ArticleJournal of medicinal chemistry2013

Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.

Yifat Berkov-Zrihen, Keith D Green, Kristin J Labby, Mark Feldman, Sylvie Garneau-Tsodikova, Micha Fridman

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Tobramycin Variants with Enhanced Ribosome-Targeting Activity.Chembiochem : a European journal of chemical biology · 2015
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yifat Berkov-ZrihenSchool of Chemistry, Tel Aviv University , Tel Aviv, 6997801, Israel.
Keith D Green
Kristin J Labby
Mark Feldman
Sylvie Garneau-Tsodikova
Micha Fridman
Tel Aviv University · ILUniversity of Michigan–Ann Arbor · US

Funding

Novel aminoglycoside adjuvants and stand-alone agents to combat tuberculosisR01AI090048 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARNEAU-TSODIKOVA, SYLVIE · 2011 to 2021
$4.4M
NIAID NIH HHS AI090048NIAID NIH HHS R01 AI090048
6 · The paper itself

Abstract

In this study, we describe the synthesis of a full set of homo- and heterodimers of three intact structures of different ribosome-targeting antibiotics: tobramycin, clindamycin, and chloramphenicol. Several aspects of the biological activity of the dimeric structures were evaluated including antimicrobial activity, inhibition of in vitro bacterial protein translation, and the effect of dimerization on the action of several bacterial resistance mechanisms that deactivate tobramycin and chloramphenicol. This study demonstrates that covalently linking two identical or different ribosome-targeting antibiotics may lead to (i) a broader spectrum of antimicrobial activity, (ii) improved inhibition of bacterial translation properties compared to that of the parent antibiotics, and (iii) reduction in the efficacy of some drug-modifying enzymes that confer high levels of resistance to the parent antibiotics from which the dimers were derived.

Indexed as

Anti-Bacterial AgentsBacteriaChloramphenicolClindamycinDimerizationDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaInhibitory Concentration 50Microbial Sensitivity TestsModels, ChemicalMolecular StructureProtein BiosynthesisRibosomesTobramycinAnti-Bacterial AgentsChloramphenicolClindamycinTobramycin

Identifiers

PMID23786357
PMCPMC3823688
OpenAlexW2075207129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.